Do not take Toujeo ® if you have low blood sugar or if you are allergic to insulin or any of the ingredients in Toujeo ®. Do not share your pen (s) with other people, even if the needle has been ...

PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up ...

Sanofi has launched its new insulin treatment Toujeo in the UK, and says it will be priced at the same level as its big seller Lantus. The pricing decision matches Sanofi's approach in the US market, ...

Two new insulins marketed by Sanofi offer improved options for patients: Toujeo is longer acting than its predecessor, Lantus. Afrezza, an inhaled insulin, is gaining praise from patients, if not from ...

New Insulin in Prefilled Pen Gets FDA Nod Sanofi announced that the Food and Drug Administration (FDA) has approved once-daily Toujeo (insulin glargine [rDNA origin]) injection 300 U/mL to improve ...

The FDA on February 25, 2015, approved the basal insulin Toujeo, which Sanofi sees as a successor to Lantus to treat patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM). Toujeo, insulin ...

A longer-acting version of the world's best-selling diabetes drug is now available in the U.K. Sanofi ($SNY) announced the availability of the long-acting basal ...

BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk ...